KN060 for dialysis patients with kidney failure
Part of Kidney & urinary clinical trials.
This study tests an experimental drug called KN060, given to people with end-stage kidney disease on dialysis, to see if it is safe and helps with blood clotting. It may be an option if you are on stable dialysis and not at high risk for bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have end-stage kidney disease and have been on stable hemodialysis three times a week for at least 3 months.
- You are not currently taking blood thinners (like warfarin or clopidogrel) or high-dose aspirin for a medical condition.
- You have not had a serious bleeding event, stroke, or major surgery in the past 3 months.
- You have no history of cancer, mechanical heart valve, or planned kidney transplant during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special filter called pHA130 to your regular dialysis treatments can better remove certain waste products from your blood and improve your quality of life. It's for people who have been on dialysis for at least 3 months and meet a few health requirements.
This study tests how a new drug called CSL300 (clazakizumab) works in the body of people with end-stage kidney disease who are on dialysis. Researchers want to understand if it's safe and how your body processes it.
This trial tests three experimental antibodies given to people with end-stage kidney disease who are on hemodialysis. It aims to see if these drugs are safe and how they affect blood clotting in this group.
This study tests an investigational drug (RVX000222) to see if it helps people with kidney failure who are on dialysis. The drug is given in two parts and may help improve heart health, which is often a concern for dialysis patients.
This trial tests a special blood-filtering treatment (hemoperfusion) for people with advanced kidney disease on regular dialysis. It aims to remove harmful substances that standard dialysis may not fully clear.
This study tests how the body handles an investigational drug called PKN605 in people with different levels of kidney function. It aims to see if the drug is safe and how it is processed when kidneys are impaired, which can help doctors decide the right dose for people with kidney disease.
Hear when a new End-Stage Renal Disease Requiring Haemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.